

RESEARCH

Open Access



Droplet digital PCR (ddPCR) for the detection and quantification of *Ureaplasma* spp.

Yanfang Huang^{1†}, Huifen Pan^{1†}, Xiaoqin Xu¹, Panpan Lv¹, Xinxin Wang² and Zhen Zhao^{1*}

Abstract

Background: *Ureaplasma* spp. are associated with various infectious diseases in females, but there is still limited evidence regarding whether they are related to nonspecific cervicitis. The aim of this study was to develop and evaluate a digital droplet PCR (ddPCR) assay for the detection and quantification of *Ureaplasma* spp. in cervical swabs.

Methods: A total of 267 non-specific cervicitis (NSC) patients and 195 asymptomatic females were included in this study. We produced standard curves for *Ureaplasma* spp. to evaluate the analytical performance of the ddPCR assay. Then, we detected and quantified the bacterial load of *Ureaplasma* spp. in cervical swabs.

Results: The prevalences of *U. parvum* were 37.8% (101/267) and 29.7% (58/195), *U. urealyticum* were 9.0% (24/267) and 8.7% (17/195) in the NSC group and control group, respectively. In addition, the median copy number of *U. parvum* was 2.5×10^4 copies/ml ($n = 101$) in the NSC group and 9.2×10^3 copies/ml ($n = 58$) in the control group. The *U. parvum* load in the NSC group was significantly higher than that in the asymptomatic individuals ($P < 0.001$), whereas the median load of *U. urealyticum* was 8.4×10^3 copies/ml ($n = 24$) and 1.4×10^3 ($n = 17$) copies/ml in the two groups, respectively, the difference was not statistically significant ($P = 0.450$).

Conclusions: Our study is the first to develop a droplet digital PCR (ddPCR) method for the detection and quantification of *Ureaplasma* spp. in clinical samples, and the method has excellent analytical performance and a wide range of clinical application prospects.

Keywords: *Ureaplasma parvum*, *Ureaplasma urealyticum*, qPCR, Droplet digital PCR, Absolute quantitation, Cervicitis

Introduction

Ureaplasma spp. has 14 known serotypes that were divided into two biovars: *Ureaplasma parvum* and *Ureaplasma urealyticum*. This pathogen is suspected to be the causative agents of non-gonococcal urethritis [1], bacterial vaginosis [2], cervicitis [3], and multiple adverse pregnancy outcomes such as spontaneous preterm birth [4], chorioamnionitis [5], and preterm premature

rupture of membranes (PPROM) [6]. In addition, some case reports have described rare invasive infections from *Ureaplasma* spp., such as idiopathic hyperammonemia [7], spontaneous bacterial pericarditis [8], multifocal abscesses [9], and osteomyelitis [10], especially in immunocompromised patients.

However, the roles of *U. parvum* and *U. urealyticum* are sometimes controversial. A meta-analysis included seven eligible case-control studies, including 1507 NGU patients and 1223 controls. The results suggested that *U. urealyticum* was significantly more prevalent in NGU patients, but *U. parvum* was found more often in controls

* Correspondence: zhaozhen_863@126.com

[†]Yanfang Huang and Huifen Pan contributed equally to this work.

¹Clinical Laboratory, Minhang Hospital, Fudan University, No. 170, Xinsong Road, Shanghai, China

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

[11]. Nevertheless, several clinical and fundamental types of research have reported that *U. parvum* induces adverse outcomes by causing a severe inflammatory response [4, 12, 13]. The controversy has been well explained by Viscardi RM et al. [14], attributing it partly due to the presence of potential confounding factors in specimens, such as *U. parvum* and *U. urealyticum* based on culture or PCR assays. These reasons make the interpretation of many previous studies extremely difficult. Moreover, some scholars have proposed that the host genetic background and bacteria load have an impact on the disease outcomes with *Ureaplasma* spp. [15, 16].

Of note, The European STI Guidelines Editorial Board issued a position statement that only people with a high *Ureaplasma* spp. load should be considered for treatment [17]. The quantitative bacterial load in all previous studies has used qPCR technology with external references [18, 19]; undoubtedly, it is a challenge to generate a standard curve. Digital droplet PCR (ddPCR) is a method of absolute nucleic acid quantification without external references and robustness to variations in PCR efficiency [20, 21]. Several studies have showed that ddPCR has much higher sensitivity and is more resistant to PCR inhibition than qPCR [22, 23]. A recent study suggested that the copy numbers obtained by qPCR were 1 to 31 times higher than those obtained by ddPCR (mean: 9.7; SD 7.7) [24], indicating that ddPCR has more accurate quantitative capabilities than qPCR.

Hence, the purpose of this study was to develop ddPCR for the detection and accurate quantification of *Ureaplasma* spp. in non-specific cervicitis patients and an asymptomatic physical examination population (control group).

Materials and methods

Study population

Patients attending the gynaecology outpatient or health clinic in Minhang Hospital, Fudan University were recruited for this study from July 2019 to November 2020. All women 1) were aged ≥ 18 years without co-infection with HIV or autoimmune diseases, 2) had exhibited symptoms of cervical discharge (purulent or mucopurulent endocervical exudate) or cervical bleeding [25], 3) had not received the gynaecologic intervention or antibiotics treatment within the preceding 3 months, 4) had not used an intrauterine contraceptive device and had been sexually active in last 3 months, 5) and were not currently pregnant or menstruating.

A total of 537 cervical samples were obtained according to protocols performed by experienced clinicians. All specimens were examined microscopically to rule out fungi and *Trichomonas vaginalis* and then subjected to HPV, *C. trachomatis*, *N. gonorrhoea*, *M. hominis*, and *M. genitalium*, *U. parvum*, and *U. urealyticum* testing by

qPCR in septuplicate. Finally, a total of 462 samples were ultimately enrolled in this study, including 267 non-specific cervicitis patients [26, 27] and 195 asymptomatic individuals.

Specimen collection and DNA extraction

Total DNA from 200 μ l fresh cervical swab samples was extracted using MiniBest Universal Genomic DNA Extraction Kit (Takara) following the manufacturer's instructions. The extracts were resuspended in 100 μ l of nuclease-free water and stored at -20°C or -80°C until use. The concentration of nucleic acids was determined with a NanoDrop 2000 Spectrophotometer (Thermo Scientific, USA). Human papillomavirus (HPV), *C. trachomatis*, *N. gonorrhoea*, *M. hominis*, and *M. genitalium* were confirmed by commercial kits based on TaqMan probes (Shanghai Kehua Bio-Engineering, or ZJ Bio-Tech Co., Ltd., Shanghai, China) according to the manufacturer's instructions. *U. parvum* serovar 1 (ATCC 27813) and *U. urealyticum* serovar 4 (ATCC 27816) were used as standard strains.

Real-time quantitative (qPCR)

QPCR amplification was performed in a total volume of 20 μ l, including the 10 μ l of Probe qPCR Mix (with UNG) (Takara), 500 nM target/reference primers, 250 nM target/reference probes, and 9 μ l of each template DNA. The qPCR conditions were as follows: 25°C for 10 min, followed by 45 cycles of 15 s at 95°C and 34 s at 60°C . Fluorescent accumulation data were analysed using ABI 7500 Software Version 2.3 (Applied Biosystems). Threshold cycle (CT) values of < 40 were defined as a positive result for the *U. parvum* and *U. urealyticum*, respectively. In addition, the quality of PCR extraction was monitored by amplifying human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in cervical swabs. CT values of > 37 suggest the failure of DNA extraction or qPCR amplification. Standard curves were generated by plotting the CT of the qPCR performed on a ten fold dilution series of purified DNA from *U. parvum* and *U. urealyticum*.

The primers and probes were designed based on the ParC gene conserved regions of *U. parvum* and *U. urealyticum*, respectively (Additional file 1), which have previously been used for qPCR [28].

U. parvum, forward: 5'-TAGTTGCTCATAAAATCA C-3',

Reverse: 5'-CGTTCCATATATAAACAGCTATAAC-3',
Probe: 5'- FAM-CTATGCGTGAAAAGATG-BHQ1-3';

U. urealyticum, forward: 5'- TAAGTGT'TTAGTA TTAGTGAGC-3';

Reverse: 5'- TGCTGCTAAAACGCTTTGTGC-3';
Probe: 5'- FAM-CACCATCACCCTTTATT-BHQ1-3'.




Fig. 1 (See legend on next page.)

(See figure on previous page.)

Fig. 1 Specificity of Primers and probes for *U. parvum* and *U. urealyticum*. **a** Positive droplets of *U. parvum* with channel amplitude signals above 6000. **b** Positive droplets of *U. urealyticum* with channel amplitude signals above 2000. **c** and **d** The primers and probes for *U. parvum* (c) and *U. urealyticum* (d) showed excellent specificity, without cross-reaction to 12 kinds of common microorganisms of the genitourinary tract, including *M. hominis*, *M. genitalium*, *C. trachomatis*, Human papilloma virus, Herpes simplex virus, *N. gonorrhoeae*, *S. agalactiae*, *S. aureus*, *E. faecium*, *E. coli*, *P. aeruginosa*, and *C. albicans*

Digital droplet PCR (ddPCR)

The same primers and probes were used for ddPCR reactions as qPCR. ddPCR was performed using a QX200 Droplet Digital PCR system (Bio-Rad). The Mastermix for ddPCR included 1× ddPCR Supermix for Probes (no dUTP), 900 nM target/reference primers, 250 nM target/reference probes, and 9 µl sample DNA. The generation of droplets was performed by the QX200 Droplet Generator according to the manufacturer's protocols. PCR amplification was carried out using an Applied Biosystems Veriti 96-Well Thermal Cycler with the following PCR conditions: 95 °C for 10 min followed by 40 cycles of denaturation at 94 °C for 30 s, 60 °C for 1 min and the enzyme was deactivated at 98 °C for 10 min. The plate was stored at 4 °C until the droplets were analysed with QX200 Droplet Reader and QuantaSoft software version 1.7.4 (Bio-Rad). The threshold between positive and negative droplet populations was set manually using per-plate positive and no-template controls as a guide.

Diagnostic performance of ddPCR for *Ureaplasma* spp.

First, the specificity of the primers and probes for *U. parvum* and *U. urealyticum* were evaluated with 12 kinds of common microorganisms of the genitourinary tract, including *M. hominis*, *M. genitalium*, *C. trachomatis*, Human papillomavirus (HPV), Herpes simplex virus (HSV), *N. gonorrhoea*, *S. agalactiae*, *S. aureus*, *E. faecium*, *E. coli*, *P. aeruginosa*, *C. albicans*. Second, the linear dynamic range of the ddPCR assay was assessed using the serial 10-fold dilutions of the standard DNA containing the target region as described previously [18]. Each dilution in the series was tested in three technical replicate wells. DNase/RNase-free water was used as the negative control (NC). The analytical limit of the assay was determined to be the concentration of the maximum dilution factor of the series in which all 10 replicates tested positive. To compare the dynamic range of ddPCR and qPCR, 10-fold serial dilutions of *U. parvum* and *U. urealyticum* were tested using the same primers/probe sets for both ddPCR and qPCR. Octuplicate results were used for intra-assay and inter-assay calculations.

Statistical analysis

Continuous variables were expressed as “the mean ± standard deviation”. Intra- and interassay coefficients of variability (CV) were calculated for methodological evaluation. Continuous variables between the two groups

were compared using Student's *t*-test. The medians were compared using Wilcoxon rank sum test. The Pearson correlation coefficient was performed to estimate the correlation between qPCR and ddPCR results of clinical samples. A *P*-value < 0.05 was considered a significant difference. The data were calculated in Stata 13.0 (StataCorp, TX, USA) and plots of linear regression were generated with GraphPad Prism 8.0 Software, Inc.

Results

Analytical performance of the ddPCR assay

We found positive droplets of *U. parvum* and *U. urealyticum* with channel amplitude signals above 6000 and 2000, respectively (Fig. 1). The ddPCR assay showed excellent specificity with no cross-reaction with twelve kinds of urogenital microorganisms. In addition, the ddPCR assay exhibited excellent intra- and inter assay coefficients of variability (CV). ddPCR has a lower intra-assay CV (0.36–0.42%) and a lower inter-assay CV (0.78–1.59%) for *U. parvum*, as well as a lower intra-assay CV (0.31–0.81%) and a lower inter-assay CV (1.43–1.48%) for the *U. urealyticum*, respectively (Table 1).


As shown in Fig. 2, the linear range of ddPCR was 3.2–3200 copies/µl with $R^2 = 0.9987$ for *U. parvum* and was 1.5–1500 copies/µl with $R^2 = 0.9980$ for *U. urealyticum*, respectively. The limit of detection of qPCR is ten times for that of ddPCR for *U. parvum* and *U. urealyticum* (Fig. 2).

Prevalence of *Ureaplasma* spp. in the NSC and control groups

There were 267 females with non-specific cervicitis in the case group, with a mean age of 40.56 (range 20–74 years; SD ± 11.06 years), and 195 asymptomatic females in the control group, with a mean age of 43.37 (range 23–68 years; SD ± 8.03 years). There were no differences

Table 1 The diagnostic performance of ddPCR for *Ureaplasma* spp.

Analytical performance	<i>U. parvum</i>	<i>U. urealyticum</i>
Specificity (%)	100	100
Liner range (copies/µl)	3.20 ~ 3200	1.50–1500
The limit of detection	0.64	1.1
Intra-assay CV (%)	0.36–0.42	0.31–0.81
Inter-assay CV (%)	0.78–1.59	1.43–1.48



in age between the two groups ($P > 0.05$). The prevalence of *U. parvum* was 37.8% (101/267) in the NSC group and 29.7% (58/195) in the control group, respectively. The prevalence of *U. urealyticum* was 9.0% (24/267) in the NSC group and 8.7% (17/195) in the control group (Fig. 3).

Correlation analysis of ddPCR and qPCR


U. parvum and *U. urealyticum* positive specimens were tested by ddPCR and qPCR simultaneously. The correlation coefficients between ddPCR and qPCR were 0.79 and 0.72 for *U. parvum* and *U. urealyticum*, respectively. However, it is worth noting that the Spearman correlation coefficient was very low when the Ct value was greater than 32 ($R^2 = 0.16$ for *U. parvum* and $R^2 = 0.27$ for *U. urealyticum*) (Fig. 4).

Absolute quantitation of *U. parvum* and *U. urealyticum*

Based on ddPCR, the median bacterial load for *U. parvum* was 2.5×10^4 copies/ml in the NSC group ($n = 101$) and 9.2×10^3 copies/ml in the control group ($n = 58$). However, the median load for *U. urealyticum* was 8.44×10^3 copies/ml in the NSC group ($n = 24$) and 1.38×10^3 copies/ml in the control group ($n = 17$) (Table 2). The load of *U. parvum* was significantly different between the NSC and control groups, whereas, the load of *U. urealyticum* was not significantly different between the two groups ($P > 0.05$).

Discussion

The purpose of this study was to develop a ddPCR assay for the detection and quantification of *Ureaplasma* spp.. According to the standard curve of the ddPCR assay for



DNA from ATCC reference strains of *Ureaplasma* spp., the assays showed excellent analytical performance. Our data suggested that the precision of ddPCR is higher than that of qPCR, especially for the low-copy specimens, similar to the report of Mahendran P[29]. It can contribute to the results that the correlation of *Ureaplasma* spp. was higher between ddPCR and qPCR methods, (Fig. 4) but very poor when the Ct value was larger than 32 in clinical samples. Thus, ddPCR would more accurately quantify the load of *Ureaplasma* spp. than qPCR assay. Nevertheless, the *Ureaplasma* spp. load was assessed by qPCR assay in previous studies [18, 30]. According to Table 2, the absolutely copy number in the non-specific cervicitis group was higher than that in the control group ($P = 0.003$). In contrast, the difference in *U. urealyticum* copy number between the two groups was not statistically significant ($P = 0.450$).

Ureaplasma spp. can be isolated from blood, amniotic fluid, cerebrospinal fluid, sputum, bronchoalveolar lavage, pleural fluid, and semen [14]. Here, we for the first time quantify the precise bacterial load of *U. parvum* and *U. urealyticum* using ddPCR technology. It is generally considered that *Ureaplasma* spp. load $\geq 10^4$ CCU/ml is a sign of active infection and may require treatment with antibiotics. The establishment of this reference value is liquid culture based. However, traditional liquid culture is only a qualitative method with relatively poor sensitivity, with false positive and false negative, as well as the inability to distinguish *U. parvum* and *U. urealyticum* [31]. Real-time PCR has become a common technique in molecular diagnosis and overcomes the above-mentioned shortcomings of liquid culture, with relative quantification through a standard curve, though the construction of a standard curve is complicated and time-

Table 2 Copy numbers of *U. parvum* and *U. urealyticum* by ddPCR in the NSC and control groups

Group	<i>U. parvum</i>			<i>U. urealyticum</i>		
	N	Median copies/ml (IQR)	P	N	Median copies/ml (IQR)	P
NSC	101	2.5×10^4 ($6.0 \times 10^3 - 1.1 \times 10^5$)	0.000	19	8.4×10^3 ($1.2 \times 10^3 - 3.1 \times 10^4$)	0.450
Control	58	9.2×10^3 ($5.9 \times 10^2 - 3.4 \times 10^4$)		14	1.4×10^3 ($5.2 \times 10^2 - 2.5 \times 10^4$)	




Fig. 4 Correlation of *U. parvum* and *U. urealyticum* between qPCR and ddPCR assays. Correlation and regression analysis of ddPCR and qPCR. Measured copies are plotted on the X-axis (converted to log₁₀) and Ct values of qPCR on the Y-axis using GraphPad Prism 8.0

consuming. Moreover, the quantitative accuracy of qPCR is easily affected by amplification efficiency and PCR inhibitors.

It's becoming gradually accepted that role of *Ureaplasma* spp. as a pathogen in multiple diseases with increasing clinical observation studies [32, 33]. In addition, several in vitro studies have demonstrated that *Ureaplasma* spp. modulate cytokine [34, 35] and pro-inflammatory responses in a dose-dependent manner [36]. Interestingly, one study indicated that a high load of *U. parvum* (10^7 CFU/ml) can significantly increase prothrombin/thrombin mRNA expression to promote the onset of PPRM but that a lower load (10^5 CFU/ml) had no significant effect [6]. It indicated that there may exist a threshold effect in various association diseases with *U. parvum* infection. Therefore, it is vital to detect the load of *Ureaplasma* spp. through more precisely quantitative technology. At this time, ddPCR, an emerging technology, is partitioned the PCR reaction into about 20,000 nm-sized droplets. Then, the relative concentration of targets, primers and probes are higher, while the inhibitor is relatively lower, which perfectly overcoming the shortcomings of conventional qPCR [23].

Our study had several limitations. First, due to the specialized instruments and consumables, ddPCR has a higher cost than qPCR, which limits its clinical application to a large extent. In addition, the prevalence of *U. urealyticum* is relatively lower and the number of populations recruited for the study was relatively small. Finally, this was a single-centre cross-sectional study, and multicenter prospective studies with a large population should be carried out to provide more evidence.

The ddPCR assay that we established has great application prospects. It can more accurately quantify the burden of *Ureaplasma* spp. than qPCR in both asymptomatic and symptomatic individuals, and monitor dynamic changes in bacterial load after the use of antibiotics. Moreover, based on its high sensitivity and high tolerance to PCR inhibitors of ddPCR, it can be used for detection of samples with low bacterial content that are readily available (urine, amniotic fluid, semen, peripheral blood, etc). Further, it can be used with chorionic amniotic tissue or lung tissue which may contain potential PCR inhibitors, promoting analysis of multiple potential diseases, such as infertility, miscarriage, chorioamnionitis,

bronchopulmonary dysplasia, bacteremia, and rare invasive infections of *Ureaplasma* spp.

In conclusion, this study is the first to report the absolute quantitative analysis of *Ureaplasma* spp. with excellent analytical performance, which may be a promising technology.

Abbreviations

ddPCR: Digital droplet PCR; *U. parvum*: *Ureaplasma parvum*; *U. urealyticum*: *Ureaplasma urealyticum*; NSC: Non-specific cervicitis; PPROM: Preterm premature rupture of membranes; HPV: Human papillomavirus; CT: Threshold cycle; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12879-021-06355-6>.

Additional file 1. Multiple sequence alignment of the ParC genes of 14 serotypes of *Ureaplasma* spp. (a) Sequence of the *U. parvum* primers/probe; (b) Sequence of the *U. ureaplasma* primers/probe.

Acknowledgements

We are sincerely obliged to Biomed-Union Co. Ltd. (Shanghai, China) for excellent technical assistance with ddPCR technology.

Authors' contributions

Yanfang Huang designed the experiments, collected clinical specimens, performed the experiments and analysed the data, and drafted the manuscript. Huifen Pan designed and performed the experiments, analysed the data and obtained funding. Xiaoqin Xu and Panpan Lv collected the clinical specimens and performed the experiments. Xinxin Wang performed the experiments. Zhen Zhao designed the experiments, analysed the data, obtained funding, supervised the study, and drafted the manuscript. All authors participated in revising of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding

This work was supported by the Minhang District Science and Technology Committee (Grant numbers 2017MHZ82).

Availability of data and materials

The data generated during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Ethical Committee of the Minhang Hospital, Fudan University.

The study abides by the ethical norms and principles for research as established by the Declaration of Helsinki. Informed consent was obtained from all subjects. All patients gave permission for the collection of their cervical swabs and for their medical records to be accessed and recorded.

Consent for publication

No.

Competing interests

The authors have declared that no conflicts of interest exist. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Author details

¹Clinical Laboratory, Minhang Hospital, Fudan University, No. 170, Xinsong Road, Shanghai, China. ²Department of Molecular Medicine, Biomed-Union Co. Ltd. Shanghai, Shanghai, China.

Received: 28 February 2021 Accepted: 18 June 2021

Published online: 11 August 2021

References

1. Beeton ML, Payne MS, Jones L. The Role of *Ureaplasma* spp. in the Development of Nongonococcal Urethritis and Infertility among Men. *Clin Microbiol Rev.* 2019;32(4):e00137–18.
2. Xiao B, Wu C, Song W, Niu X, Qin N, Liu Z, et al. Association analysis on recurrence of bacterial vaginosis revealed Microbes and clinical variables important for treatment outcome. *Front Cell Infect Mi.* 2019;9:189.
3. Lusk MJ, Garden FL, Rawlinson WD, Naing ZW, Cumming RG, Konecny P. Cervicitis aetiology and case definition: a study in Australian women attending sexually transmitted infection clinics. *Sex Transm Infect.* 2016; 92(3):175–81. <https://doi.org/10.1136/sextrans-2015-052332>.
4. Rittenschöber-Böhm J, Waldhoer T, Schulz SM, Pimpel B, Goeral K, Kasper DC, et al. Vaginal *Ureaplasma parvum* serovars and spontaneous preterm birth. *Am J Obstet Gynecol.* 2019;220(6):591–4.
5. Sweeney EL, Dando SJ, Kallapur SG, Knox CL. The human *Ureaplasma* species as causative agents of Chorioamnionitis. *Clin Microbiol Rev.* 2017; 30(1):349–79. <https://doi.org/10.1128/CMR.00091-16>.
6. Feng L, Allen TK, Marinello WP, Murtha AP. Infection-induced thrombin production: a potential novel mechanism for preterm premature rupture of membranes (PPROM). *Am J Obstet Gynecol.* 2018;219(1):101.
7. Smith M, Crews JD, Cheek N, Srivastava R, Appachi E. Hyperammonemic encephalopathy due to *Ureaplasma parvum* infection in an immunocompromised child. *Pediatrics.* 2019;144(2):e20190601. <https://doi.org/10.1542/peds.2019-0601>.
8. Contini C, Rotondo JC, Magagnoli F, Maritati M, Seraceni S, Graziano A, et al. Investigation on silent bacterial infections in specimens from pregnant women affected by spontaneous miscarriage. *J Cell Physiol.* 2018;234(1): 100–7. <https://doi.org/10.1002/jcp.26952>.
9. Diaz Pallares C, Griener T, Vaughan S. *Ureaplasma urealyticum* disseminated multifocal abscesses in an immunocompromised adult patient: a case report. *BMC Infect Dis.* 2020;20(1):47.
10. Frangogiannis NG, Cate TR. Endocarditis and *Ureaplasma urealyticum* osteomyelitis in a hypogammaglobulinemic patient. A case report and review of the literature. *J Infect.* 1998;37(2):181–4. [https://doi.org/10.1016/S0163-4453\(98\)80174-6](https://doi.org/10.1016/S0163-4453(98)80174-6).
11. Zhang N, Wang R, Li X, Liu X, Tang Z, Liu Y. Are *Ureaplasma* spp. a Cause of Nongonococcal Urethritis? A Systematic Review and Meta-Analysis. *Plos One.* 2014;9(12):e113771.
12. Payne MS, Ireland DJ, Watts R, Nathan EA, Furfaro LL, Kemp MW, et al. *Ureaplasma parvum* genotype, combined vaginal colonisation with *Candida albicans*, and spontaneous preterm birth in an Australian cohort of pregnant women. *BMC Pregnancy Childb.* 2016;16(1):312.
13. Motomura K, Romero R, Xu Y, Theis KR, Galaz J, Winters AD, et al. Intra-amniotic infection with *Ureaplasma parvum* causes preterm birth and neonatal mortality that are prevented by treatment with clarithromycin. *MBIO.* 2020;11(3):e720–97.
14. Viscardi RM. *Ureaplasma* species: role in diseases of prematurity. *Clin Perinatol.* 2010;37(2):393–409. <https://doi.org/10.1016/j.clp.2009.12.003>.
15. von Chamier M, Allam A, Brown MB, Reinhard MK, Reyes L. Host genetic background impacts disease outcome during intrauterine infection with *Ureaplasma parvum*. *PLoS One.* 2012;7(8):e44047. <https://doi.org/10.1371/journal.pone.0044047>.
16. Kacerovsky M, Pliskova L, Bolehovska R, Musilova I, Hornychova H, Tambor V, et al. The microbial load with genital *mycoplasmas* correlates with the degree of histologic chorioamnionitis in preterm PROM. *Am J Obstet Gynecol.* 2011;205(3):211–3.
17. Horner P, Donders G, Cusini M, Gombert M, Jensen JS, Unemo M. Should we be testing for urogenital *Mycoplasma hominis*, *Ureaplasma parvum* and *Ureaplasma urealyticum* in men and women?—a position statement from the European STI guidelines editorial board. *J Eur Acad Dermatol.* 2018;32(11): 1845–51. <https://doi.org/10.1111/jdv.15146>.
18. Liu L, Cao G, Zhao Z, Zhao F, Huang Y. High bacterial loads of *Ureaplasma* may be associated with non-specific cervicitis. *Scand J Infect Dis.* 2014;46(9): 637–41. <https://doi.org/10.3109/00365548.2014.922696>.
19. Frølund M, Lidbrink P, Wikström A, Cowan S, Ahrens P, Jensen J. Urethritis-associated pathogens in urine from men with non-gonococcal urethritis: a case-control study. *Acta Dermato Venereologica.* 2016;96(5):689–94. <https://doi.org/10.2340/00015555-2314>.

20. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. *Nat Methods*. 2013;10(10):1003–5. <https://doi.org/10.1038/nmeth.2633>.
21. Kuypers J, Jerome KR. Applications of digital PCR for clinical microbiology. *J Clin Microbiol*. 2017;55(6):1621–8. <https://doi.org/10.1128/JCM.00211-17>.
22. Song N, Tan Y, Zhang L, Luo W, Guan Q, Yan M, et al. Detection of circulating *Mycobacterium tuberculosis*-specific DNA by droplet digital PCR for vaccine evaluation in challenged monkeys and TB diagnosis. *Emerg Microbes Infect*. 2018;7(1):1–9.
23. Poh TY, Ali NATB, Chan LLY, Tiew PY, Chotirmall SH. Evaluation of droplet digital polymerase chain reaction (ddPCR) for the absolute quantification of *Aspergillus* species in the human airway. *Int J Mol Sci*. 2020;21(9):3043. <https://doi.org/10.3390/ijms21093043>.
24. Lillsunde Larsson G, Helenius G. Digital droplet PCR (ddPCR) for the detection and quantification of HPV 16, 18, 33 and 45 - a short report. *Cell Oncol*. 2017;40(5):521–7. <https://doi.org/10.1007/s13402-017-0331-y>.
25. Workowski KA. Sexually transmitted diseases treatment guidelines, 2015. *Ann Emerg Med*. 2015;66(5):526–8.
26. Nyirjesy P. Nongonococcal and nonchlamydial cervicitis. *Curr Infect Dis Rep*. 2001;3(6):540–5. <https://doi.org/10.1007/s11908-001-0092-6>.
27. Lus MJ, Konecny P. Cervicitis: a review. *Curr Opin Infect Dis*. 2008;21:49–55.
28. Lu L, Yu-hua JI, Zhen Z, Fang Z, Guo-jun C, Fu-zhi X, et al. Clinical application of genotyping detection of human mycoplasma urealyticum based on parC gene sequences. *Chin J Microbiol Immunol*. 2011;31(9):843–6.
29. Mahendran P, Liew JWK, Amir A, Ching X, Lau Y. Droplet digital polymerase chain reaction (ddPCR) for the detection of *Plasmodium knowlesi* and *Plasmodium vivax*. *Malaria J*. 2020;19(1):241.
30. Contini C, Rotondo JC, Magagnoli F, Maritati M, Seraceni S, Graziano A, et al. Investigation on silent bacterial infections in specimens from pregnant women affected by spontaneous miscarriage. *J Cell Physiol*. 2019;234(1):100–7. <https://doi.org/10.1002/jcp.26952>.
31. Zhao F, Feng X, Lv P, Xu X, Zhao Z. Real-time PCR assay may be used to verify suspicious test results of *Ureaplasmas* spp from the liquid culture method. *J Microbiol Meth*. 2020;169:105831.
32. Saha SK, Schrag SJ, El Arifeen S, Mullany LC, Shahidul Islam M, Shang N, et al. Causes and incidence of community-acquired serious infections among young children in South Asia (ANISA): an observational cohort study. *Lancet*. 2018;392(10142):145–59. [https://doi.org/10.1016/S0140-6736\(18\)31127-9](https://doi.org/10.1016/S0140-6736(18)31127-9).
33. Bharat A, Cunningham SA, Scott Budinger GR, Kreisel D, DeWet CJ, Gelman AE, et al. Disseminated *Ureaplasma* infection as a cause of fatal hyperammonemia in humans. *Sci Transl Med*. 2015;7(284):283r–4r.
34. Glaser K, Silwedel C, Fehrholz M, Waaga-Gasser AM, Henrich B, Claus H, et al. *Ureaplasma* species differentially modulate pro- and anti-inflammatory cytokine responses in newborn and adult human monocytes pushing the state toward pro-inflammation. *Front Cell Infect Mi*. 2017;7:484.
35. Pavlidis I, Spiller OB, Sammut Demarco G, MacPherson H, Howie SEM, Norman JE, et al. Cervical epithelial damage promotes *Ureaplasma parvum* ascending infection, intrauterine inflammation and preterm birth induction in mice. *Nat Commun*. 2020;11(1):199.
36. Noh EJ, Kim DJ, Lee JY, Park JH, Kim J, Han JW, et al. *Ureaplasma Urealyticum* infection contributes to the development of pelvic endometriosis through toll-like receptor 2. *Front Immunol*. 2019;10. <https://doi.org/10.3389/fimmu.2019.02373>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

